ACSR for the year ended on 31st March, 2025
Awaiting price reaction for this filing.
Murae Organisor Limited (formerly Earum Pharmaceuticals) submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2025, audited by Jay Pandya & Associates, Company Secretaries. BSE imposed fines during the year for two non-compliances: ₹3,540 for not properly constituting the Nomination and Remuneration Committee (Q1 FY25), and approximately ₹25,370 for delayed disclosure of related party transactions on a consolidated basis (H1 FY25). The company also had a backlog of prior-year non-compliances (late filing of annual report, financial results, ACSR, and delayed appointment of a Company Secretary after the August 2023 resignation), which were subsequently rectified, with BSE penalties already imposed. A notable red flag: SEBI issued a summons to the company on March 19, 2025 for production of documents before its Investigative Authority under Sections 11(2), 11C(2) and 11C(3) of the SEBI Act, 1992, and investigation proceedings are currently ongoing. Additionally, certain company records were not made available for inspection during the review.
Shareholders should treat the ongoing SEBI investigation as a significant overhang on the stock, as outcomes can range from a clean chit to penalties or further action. The repeated compliance lapses and BSE fines point to weak governance discipline, which may concern institutional and retail investors.